8 Results for "

acute peritonitis model

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "acute peritonitis model" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-160109
Target:  

Mucin

Research Areas:  

Inflammation/Immunology Cancer

Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research .
loading...
    loading...
Cat. No.: HY-148258
CAS No.: 2238822-07-4
Purity:  99.54%
GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation. GDC-2394 could be used to study gouty arthritis.
loading...
    loading...
Cat. No.: HY-163159
CAS No.: 2409825-32-5
NP3-562 is an orally active NLRP3 Inhibitor. NP3-562 inhibits IL-1β release in the supernatant of Nigericin (HY-127019)-stimulated THP-1 cells (IC50 = 66 nM), human whole blood (IC50 = 214 nM) and a mouse acute peritonitis model. NP3-562 can be used for the study of acute peritonitis .
loading...
    loading...
Cat. No.: HY-178953
NLRP3-IN-84 (Compound 32) is a NLRP3 inflammasome inhibitor. NLRP3-IN-84 can interfere with the oligomerization process of NLRP3 by inhibiting the activity of NLRP3 ATPase (IC50 = 158.4 nM). NLRP3-IN-84 inhibits Caspase-1 (IC50 = 27.7 nM), IL-1β release (PBMC: IC50 = 19.5 nM; mPBMC: IC50 = 24.2 nM), and ASC plaque formation (IC50 = 131 nM). NLRP3-IN-84 has no inhibitory activity on NLRC4 and AIM2 inflammasomes. NLRP3-IN-84 exhibits significant in vivo anti-inflammatory effects in a mouse acute peritonitis model. NLRP3-IN-84 can be used for the study of NLRP3-related inflammatory diseases .
loading...
    loading...
Cat. No.: HY-170233
NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models .
loading...
    loading...
Cat. No.: HY-160109A
CAS No.: 1334320-77-2
Target:  

Mucin

Research Areas:  

Inflammation/Immunology

Ac5GalNTGc epimer is an analogue of hexosamine and the racemate of Ac5GalNTGc (HY-160109). Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research .
loading...
    loading...
Cat. No.: HY-19086
CAS No.: 122454-69-7
Target:  

COX Lipoxygenase

Research Areas:  

Inflammation/Immunology

SKF-105809 is a dual-action inhibitor of lipoxygenase and COX. SKF-105809 inhibits edema and inflammatory cell infiltration in mouse models of ear, paw, and peritoneum inflammation. SKF-105809 inhibits the production of relevant acute-phase reactive proteins in a mouse model of arthritis. SKF-105809 exhibits analgesic activity in a mouse abdominal contraction test and inhibits ulceration. SKF-105809 can be used in research on inflammatory and immune system diseases such as peritonitis and arthritis .
loading...
    loading...
Cat. No.: HY-184651
CAS No.: 3055155-53-5
NLRP3-IN-93 is an orally active, blood-brain barrier-permeable NLRP3 inhibitor. NLRP3-IN-93 binds to the NACHT domain, blocks inflammasome assembly, and inhibits downstream IL-1β release, without significantly inhibiting various CYP isoforms. NLRP3-IN-93 demonstrates dose-dependent efficacy in mouse models of acute inflammation and Parkinson's disease, and exhibits good tolerability and an acceptable safety window in rats and dogs. NLRP3-IN-93 can be used in research on Parkinson's disease .
loading...
    loading...